Showing results (1641-1650 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|February 8, 2000
Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux diseaseN O Stålhammar, J Carlsson, R Peacock, et al.Pharmacoeconomics|February 8, 2000
Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes. A Canadian hospital perspectiveR M Balen, C A Marra, P J Zed, et al.Pharmacoeconomics|February 8, 2000
Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UKT N Flynn, S M Kelsey, D L Hazel, et al.Pharmacoeconomics|February 8, 2000
Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infectionsD J Walters, J S Solomkin, J A PaladinoPharmacoeconomics|October 28, 1999
Treatment of locally advanced pancreatic carcinoma in Sweden. A health economic comparison of palliative treatment with best supportive care versus palliative treatment with gemcitabine in combination with best supportive careG Ragnarson-Tennvall, N WilkingPharmacoeconomics|October 28, 1999
Vinorelbine in advanced non-small cell lung cancer. A pharmacoeconomic reviewA J Coukell, S Noble, D FauldsPharmacoeconomics|October 28, 1999
Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studiesD A Revicki, L FrankPharmacoeconomics|October 28, 1999
Outstanding regulatory aspects in the European pharmaceutical marketP Kanavos, E MossialosPharmacoeconomics|October 28, 1999
Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribingF Andersson, C Cline, T Rydén-Bergsten, et al.Pharmacoeconomics|October 28, 1999
Hospital selection for unit cost estimates in multicentre economic evaluations. Does the choice of hospitals make a difference?R Goeree, A Gafni, M Hannah, et al.Pageof 336